The second quarter of 2019 will feature major catalysts for the gene therapy onasemnogene abeparvovec (Zolgensma; to be commercialized by Novartis), the opioid conjugate NKTR-181 (developed by Nektar Therapeutics) and the monoclonal antibody (mAb) IFX-1 (developed by InflaRx). Both Zolgensma and NKTR-181 face regulatory approval decisions from the FDA in their respective indications of spinal muscular atrophy (SMA) and chronic lower back pain (CLBP). InflaRx will be reporting top-line results from its phase IIb SHINE study of IFX-1 for the treatment of hidradenitis suppurativa.

Enjoying our latest content?
Log in or create an account to continue

  • Access the most recent journalism from Nature's award-winning team
  • Explore the latest features & opinion covering groundbreaking research
Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD